Last reviewed · How we verify

oral suzetrigine — Competitive Intelligence Brief

oral suzetrigine (oral suzetrigine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective sodium channel blocker. Area: Pain management / Neurology.

marketed Selective sodium channel blocker Voltage-gated sodium channels (Nav) Pain management / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

oral suzetrigine (oral suzetrigine) — University of Louisville. Suzetrigine is a selective sodium channel blocker that reduces neuronal excitability and pain signal transmission.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
oral suzetrigine TARGET oral suzetrigine University of Louisville marketed Selective sodium channel blocker Voltage-gated sodium channels (Nav)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective sodium channel blocker class)

  1. University of Louisville · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). oral suzetrigine — Competitive Intelligence Brief. https://druglandscape.com/ci/oral-suzetrigine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: